Your MAH Partner in Europe and UK

As companies approach EU and UK submission, the focus is understandably on dossier readiness, regulatory strategy, and timelines.

However, one critical decision is often left unresolved until late in the process:

Who will hold the Marketing Authorisation (MA)?

This is not simply an administrative detail. It is a strategic decision that will shape how your product is managed, governed, and maintained throughout its lifecycle.

Why the MAH Decision Matters More Than You Think

The Marketing Authorisation Holder (MAH) carries full legal responsibility for a medicinal product once it is approved. This includes:

• Pharmacovigilance system ownership
• Product quality and batch certification oversight
• Ongoing regulatory compliance and lifecycle management
• Inspection readiness across multiple functions

In practical terms, the MAH defines your operating model post-approval.

And yet, in many organisations, this decision is deferred – treated as something to finalise once approval is in sight.

Common Approaches to MAH – and Their Risks

In our experience, companies preparing EU or UK submissions typically follow one of three paths.

1. Holding the MA Internally

This approach gives full control – but comes with significant requirements.

To operate effectively as an MAH, you need:

• A fully established pharmacovigilance system (including a QPPV)
• A functioning quality management system
• Regulatory capability to manage variations and lifecycle activities
• Inspection-ready processes from day one

The challenge:
These capabilities are often underestimated and built under time pressure as submission deadlines approach.

2. A Fragmented Outsourcing Model

Some organisations outsource elements of MAH responsibility – such as pharmacovigilance or regulatory submissions – to different providers.

While this can work in the short term, it often leads to:

• Siloed responsibilities
• Gaps in oversight
• Increased coordination burden internally
• Higher inspection risk due to lack of system integration

The challenge:
No single party has full accountability, and the burden of integration falls back on the sponsor.

3. An Integrated MAH Model

An alternative approach is to implement a fully integrated MAH model, where regulatory, quality, and pharmacovigilance responsibilities are managed within a single, aligned framework.

This provides:

• Clear accountability and a single point of contact
• Pre-established systems and governance
• Reduced complexity during submission and post-approval
• Scalability as your portfolio grows

The advantage:
The operating model is designed holistically – rather than assembled under pressure.

The Timing Problem: Why This Decision Comes Too Late

In many cases, the MAH model is only seriously considered in the final stages before submission – or even after approval.

By that point:

• Timelines are constrained
• Internal teams are focused on submission delivery or launch
• Vendor selection becomes reactive rather than strategic

The result is often a suboptimal structure that introduces risk and inefficiency from the outset.

Why MAH Strategy Should Be Defined Before Submission

The most effective MAH models are not implemented after approval – they are designed before submission.

Defining your MAH approach early allows you to:

• Align regulatory, quality, and PV strategies from the start
• Ensure systems are inspection-ready at approval
• Avoid rushed hiring or fragmented outsourcing decisions
• Build a scalable foundation for future products

Just as importantly, it removes uncertainty at a critical stage of the product lifecycle, and leaves internal resource focussed on maximising launch.

A More Strategic Approach to EU and UK Submissions

For companies preparing Marketing Authorisation Applications (MAAs) in the EU and UK, the question is not simply:

“Who will hold the MA?”

It is:

“What operating model will support this product from submission through to full lifecycle management?”

Answering that question early enables a more controlled, efficient, and compliant transition from development to commercialisation.

Conclusion

The decision around Marketing Authorisation Holder is often underestimated – but it has far-reaching implications for compliance, scalability, and operational efficiency.

Leaving it too late can result in unnecessary complexity and risk at the point where your organisation is least able to absorb it.

For many companies, defining an MAH strategy before submission – and considering an integrated approach – provides a more robust and scalable solution.

If you are approaching submission and have not yet defined your MAH model, now is the time to do so.

Integral Pharma Solutions offers a fully integrated MAH service, ensuring you are inspection-ready at approval and supported throughout the product lifecycle.

Get in touch to explore how we can support your EU and UK submissions.